Zidovudine pharmacokinetics during pregnancy.
As the indications for zidovudine (ZDV) treatment in human immunodeficiency virus-infected individuals expand, we anticipate an increased use of this drug during pregnancy. We report pharmacokinetics data from a patient studied both in the third trimester and intrapartum. ZDV peak-plasma levels and serum half-lives were comparable to nonpregnant adults. High concentrations of ZDV and its glucuronide metabolite were found in umbilical cord blood and in amniotic fluid.
Sperling
R S
RS
Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine, New York, New York 10029.
Roboz
J
J
Dische
R
R
Silides
D
D
Holzman
I
I
Jew
E
E
D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007231:Infant, Newborn; D008895:Milk, Human / Q000737:chemistry; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000378:metabolism*; D015215:Zidovudine / Q000032:analysis / Q000493:pharmacokinetics* / Q000627:therapeutic use
D015215:Zidovudine